Form 8-K LEXICON PHARMACEUTICALS, For: Apr 29
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St futures rise as Fed rate hike lifts long-standing overhang
- Oil prices extend losses as supply disruption fears ease
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
Lexicon Pharma (LXRX) Announces One-for-Seven Reverse Split
April 29, 2015 5:29 PM EDTLexicon Pharma (NASDAQ: LXRX) announces that it will effect a reverse stock split at a ratio of one share of newly issued common stock for each seven shares of issued and outstanding common stock. Lexicon anticipates that the reverse stock split will be effective at 5:00 p.m. Eastern Time on May 20, 2015, and that its common stock will commence trading on a split-adjusted basis as of the opening of trading on May 21, 2015.
Lexicon stockholders previously approved an amendment to Lexicon's certificate of incorporation to effect the reverse stock split at the discretion... More
Lexicon Pharma (LXRX) Reports In-Line Q1 Loss of 4c/Share
April 29, 2015 5:28 PM EDTLexicon Pharma (NASDAQ: LXRX) reported Q1 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $1.8 million versus the consensus estimate of $1.1 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
... More